RecruitingNCT05711732

Busulfan Sample Collection Study

Collection of Plasma Samples Using Sodium Heparin From Subjects Undergoing Intravenous Busulfan Treatment


Sponsor

Saladax Biomedical, Inc.

Enrollment

150 participants

Start Date

Feb 8, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Busulfan (Busulfex®) is an alkylating drug used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Busulfan has wide inter- and intra-patient pharmacokinetic variability resulting in variable exposure leading to increased risk of toxicities or sub-optimal treatment outcomes. Therapeutic drug monitoring of busulfan using patient plasma samples would benefit clinicians by providing the ability to personalize the dose to achieve a target busulfan exposure.


Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying MyCare Oncology Busulfan Assay Kit for people with subjects treated with busulfan. The study is currently recruiting participants at 2 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTMyCare Oncology Busulfan Assay Kit

This is a sample collection study only. Patient treatment will not be determined by the outcome of the analytical test results.


Locations(2)

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Chicago, Illinois, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05711732